ORIC Pharmaceuticals (ORIC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec16

Wells Fargo Raises ORIC Pharmaceuticals Target Price to $25

04:34

Dec8

Roth MKM Reiterates Buy Rating on ORIC Pharmaceuticals with Price Target

14:17

Dec6

ORIC Pharmaceuticals Announces Positive Phase 1b Results for Enozertinib in EGFR Exon 20 Mutated NSCLC

01:00

Dec3

Oric Pharmaceuticals Presents Enozerinib Trial Data at ESMO Asia Conference

21:01

Dec1

Oric Pharmaceuticals to Release New Clinical Trial Data on Enozertinib at ESMO Asia

13:00

Nov20

Evercore ISI Group Initiates Coverage of Oric Pharmaceuticals Stock with an 'Outperform' Rating

14:20

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -32.59 M, EPS -0.3293

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -36.36 M, EPS -0.4653

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -30.02 M, EPS -0.4225

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change